Lilly enters psychedelic drug race with up to $3.8 billion AtaiBeckley deal
16/07/2026 11:47
Lilly enters psychedelic drug race with up to $3.8 billion AtaiBeckley deal July 16 (Reuters) - Eli Lilly LLY.N said on Thursday it would acquire psychedelic drug developer AtaiBeckley ATAI.O for up to $3.8 billion, entering the race to develop psychedelic treatments for depression and other mental health disorders.
(Reporting by Kunal Das and Puyaan Singh in Bengaluru; Editing by Sriraj Kalluvila)
Recent news on AtaiBeckley
See all newsFDA to hold public hearing on psychedelic drugs as Trump-driven push gathers pace
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:28 AM
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:28 AM
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM